Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (BMY)
NYSE:BMY
Holding BMY?
Track your performance easily
BMY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$39.35 - $61.08
Previous Close$58.23
Volume11.24M
Average Volume (3M)11.00M
Market Cap
$118.10B
Enterprise Value$159.82B
Total Cash (Recent Filing)$8.09B
Total Debt (Recent Filing)$49.75B
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Feb 06, 2025EPS Estimate
$1.47Last Dividend Ex-Date
Oct 04, 2024Dividend Yield4.22%
Share Statistics
EPS (TTM)-3.60
Shares Outstanding2,028,176,674
10 Day Avg. Volume14,371,204
30 Day Avg. Volume10,999,613
Standard Deviation0.06
R-Squared0.13
Alpha-0.00074
Financial Highlights & Ratios
Price to Book (P/B)6.89
Price to Sales (P/S)2.40
Price to Cash Flow (P/CF)5.20
P/FCF Ratio5.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.37
Enterprise Value/Gross Profit4.66
Enterprise Value/Ebitda35.16
Forecast
1Y Price Target
$58.21Price Target Upside0.57% Upside
Rating ConsensusHold
Number of Analyst Covering17
Bristol-Myers Squibb News
Bulls Say, Bears Say
Bulls Say
Leadership And Growth OutlookA new CEO is leading Bristol-Myers Squibb Company with a refreshed growth outlook, suggesting potential positive changes for the company's future.
Pipeline And Revenue PotentialMilvexian's sales projections have been increased after a positive trial update, indicating potential for significant future revenue.
Product Launch And Market OpportunityCobenfy is being watched to see if it can become a $10bn+ drug given BMY's leading position in the muscarinic space.
Bears Say
Patent ExpirationsBristol-Myers Squibb Company is facing significant challenges due to ongoing and imminent patent expirations for key products like Revlimid, Eliquis, and Opdivo.
Product Launch PerformanceSotyktu, Zeposia, and Krazati launches remain underwhelming.
Revenue And Margin OutlookThe company will face meaningful revenue and margin compression in the '26-'30 period, which does not appear to be reflected at current valuation.
---
Ownership Overview
0.07% Insiders
21.58% Mutual Funds
15.32% Other Institutional Investors
39.07% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMY FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was $39.35 and its highest was $61.08 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Currently, no data Available
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Feb 06, 2025 which is in 77 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Oct 31, 2024. The company reported $1.8 earnings per share for the quarter, beating the consensus estimate of $1.494 by $0.306.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of $0.6 which represents an annual dividend yield of 4.22%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is $1.47.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,028,176,600 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of $1.8 in its last earnings report, beating expectations of $1.494. Following the earnings report the stock price went up 5.906%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Among the largest hedge funds holding Bristol-Myers Squibb’s share is PRIMECAP Management Co. It holds Bristol-Myers Squibb’s shares valued at 1B.
---
Bristol-Myers Squibb Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$58.21 (0.57% Upside)
$58.21 (0.57% Upside)
Blogger Sentiment
Bullish
BMY Sentiment 98%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 499.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $61.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.35%
12-Months-Change
Fundamentals
Return on Equity
-31.46%
Trailing 12-Months
Asset Growth
2.64%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
---
BMY Company Deck
---
BMY Earnings Call
Q3 2024
0:00 / 0:00
---
BMY Revenue Breakdown
27.12% Eliquis
20.02% Opdivo
13.55% Revlimid
8.00% Orencia
31.31% Other
---
BMY Stock 12 Month Forecast
Average Price Target
$58.21
▲(0.57% Upside)
Technical Analysis
Best Analysts Covering BMY
1 Year
1 Year Success Rate
13/20 ratings generated profit
1 Year Average Return
+3.08%
reiterated a sell rating 6 days ago
Copying Terence Flynn's trades and holding each position for 1 Year would result in 65.00% of your transactions generating a profit, with an average return of +3.08% per trade.
---